Phenotype measures set:   Wiltshire4   monocytes_Sel

ID, description, units MPD:52473   monocytes_Sel   monocytes, percent viability   [%]
selumetinib study
Measures • dose [µM]:    • control    • 0.046    • 0.137    • 1.235    • 11.1    • 100
Data set, strains Wiltshire4   inbred w/CC7   34 strains     sex: m     age: 10wks
Procedure immune cell quantification
Comparisoncontrol group vs. multiple treatment / dosage groups
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options

Wiltshire4 - monocytes, percent viability





  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary     

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
dose 5 1567.7569 313.5514 1.974 0.0807
strain 33 30509.6172 924.5339 5.8205 < 0.0001
dose:strain 165 34688.8149 210.2352 1.3236 0.0098
Residuals 594 94351.7607 158.8413

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDDrug or
challenge
Description and varname PanelStrains
tested
SexAge
Wiltshire4 52473 immune cell quantification selumetinib monocytes, percent viability   [%]   control   monocytes_Sel_ctrl inbred w/CC7 34 m 10wks
Wiltshire4 52474 immune cell quantification selumetinib monocytes, percent viability   [%]   dose: 0.046 µM   monocytes_Sel_A inbred w/CC7 34 m 10wks
Wiltshire4 52475 immune cell quantification selumetinib monocytes, percent viability   [%]   dose: 0.137 µM   monocytes_Sel_B inbred w/CC7 34 m 10wks
Wiltshire4 52476 immune cell quantification selumetinib monocytes, percent viability   [%]   dose: 1.235 µM   monocytes_Sel_C inbred w/CC7 34 m 10wks
Wiltshire4 52477 immune cell quantification selumetinib monocytes, percent viability   [%]   dose: 11.1 µM   monocytes_Sel_D inbred w/CC7 34 m 10wks
Wiltshire4 52478 immune cell quantification selumetinib monocytes, percent viability   [%]   dose: 100 µM   monocytes_Sel_E inbred w/CC7 34 m 10wks